🇺🇸 FDA
Pipeline program

SSGJ-705

SSGJ-705-ST-I-01

Phase 1 small_molecule active

Quick answer

SSGJ-705 for Receptor, ErbB-2 is a Phase 1 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Receptor, ErbB-2
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials